Factors predicting peritoneal recurrence in advanced gastric cancer: Implication for adjuvant intraperitoneal chemotherapy

Ju Hee Lee, Sang Yong Son, Chang Min Lee, Sang Hoon Ahn, Do Joong Park, Hyung Ho Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Despite adjuvant chemotherapy, patients with advanced gastric cancer (AGC) often develop recurrence, and the peritoneum is the most common site of recurrence. Therefore, intraperitoneal chemotherapy (IPC) has been proposed as a treatment option. The aim of this study was to select the eligible patients for application of IPC. Methods: A total of 805 patients with AGC who underwent curative D2 gastrectomy between May 2003 and December 2009 were included in this study. Risk factors for peritoneal recurrence were analyzed. Results: Recurrence developed in 245 patients (30.4 %). The first site of recurrence was the peritoneum in 144 patients (58.8 %), and the 5-year peritoneal recurrence-free survival was 79.3 %. Depth of tumor invasion ≥T3, extensive lymph node metastasis (N3), Bormann type 4, infiltrative type (Ming's classification), and venous invasion were independent risk factors for peritoneal recurrence. In subgroup analysis with patients who had received adjuvant chemotherapy (n = 481), depth of tumor invasion ≥T3, Bormann type 4, infiltrative type (Ming's classification), and venous invasion were independent risk factors for peritoneal recurrence. When a peritoneal recurrence risk index was made with each risk factor assigned 1 point (2 points for T4 stage), peritoneal recurrence rates with 0, 1, 2, 3, 4, or 5 points were 0 %, 3.9 %, 13.1 %, 33.3 %, 44.0 %, and 72.0 %, respectively, in those patients. Conclusions: Patients at higher risk for peritoneal recurrence can be identified from the findings of this study. Further prospective studies are required to evaluate the usefulness of IPC for these patients.

Original languageEnglish
Pages (from-to)529-536
Number of pages8
JournalGastric Cancer
Volume17
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Stomach Neoplasms
Recurrence
Peritoneum
Drug Therapy
Gastrectomy
Neoplasms
Lymph Nodes
Prospective Studies
Neoplasm Metastasis
Survival

Keywords

  • Advanced gastric cancer
  • Intraperitoneal chemotherapy
  • Peritoneal recurrence

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Factors predicting peritoneal recurrence in advanced gastric cancer : Implication for adjuvant intraperitoneal chemotherapy. / Lee, Ju Hee; Son, Sang Yong; Lee, Chang Min; Ahn, Sang Hoon; Park, Do Joong; Kim, Hyung Ho.

In: Gastric Cancer, Vol. 17, No. 3, 01.01.2014, p. 529-536.

Research output: Contribution to journalArticle

Lee, Ju Hee ; Son, Sang Yong ; Lee, Chang Min ; Ahn, Sang Hoon ; Park, Do Joong ; Kim, Hyung Ho. / Factors predicting peritoneal recurrence in advanced gastric cancer : Implication for adjuvant intraperitoneal chemotherapy. In: Gastric Cancer. 2014 ; Vol. 17, No. 3. pp. 529-536.
@article{f107ed8c10e74baaa862967577a89428,
title = "Factors predicting peritoneal recurrence in advanced gastric cancer: Implication for adjuvant intraperitoneal chemotherapy",
abstract = "Background: Despite adjuvant chemotherapy, patients with advanced gastric cancer (AGC) often develop recurrence, and the peritoneum is the most common site of recurrence. Therefore, intraperitoneal chemotherapy (IPC) has been proposed as a treatment option. The aim of this study was to select the eligible patients for application of IPC. Methods: A total of 805 patients with AGC who underwent curative D2 gastrectomy between May 2003 and December 2009 were included in this study. Risk factors for peritoneal recurrence were analyzed. Results: Recurrence developed in 245 patients (30.4 {\%}). The first site of recurrence was the peritoneum in 144 patients (58.8 {\%}), and the 5-year peritoneal recurrence-free survival was 79.3 {\%}. Depth of tumor invasion ≥T3, extensive lymph node metastasis (N3), Bormann type 4, infiltrative type (Ming's classification), and venous invasion were independent risk factors for peritoneal recurrence. In subgroup analysis with patients who had received adjuvant chemotherapy (n = 481), depth of tumor invasion ≥T3, Bormann type 4, infiltrative type (Ming's classification), and venous invasion were independent risk factors for peritoneal recurrence. When a peritoneal recurrence risk index was made with each risk factor assigned 1 point (2 points for T4 stage), peritoneal recurrence rates with 0, 1, 2, 3, 4, or 5 points were 0 {\%}, 3.9 {\%}, 13.1 {\%}, 33.3 {\%}, 44.0 {\%}, and 72.0 {\%}, respectively, in those patients. Conclusions: Patients at higher risk for peritoneal recurrence can be identified from the findings of this study. Further prospective studies are required to evaluate the usefulness of IPC for these patients.",
keywords = "Advanced gastric cancer, Intraperitoneal chemotherapy, Peritoneal recurrence",
author = "Lee, {Ju Hee} and Son, {Sang Yong} and Lee, {Chang Min} and Ahn, {Sang Hoon} and Park, {Do Joong} and Kim, {Hyung Ho}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10120-013-0306-2",
language = "English",
volume = "17",
pages = "529--536",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Factors predicting peritoneal recurrence in advanced gastric cancer

T2 - Implication for adjuvant intraperitoneal chemotherapy

AU - Lee, Ju Hee

AU - Son, Sang Yong

AU - Lee, Chang Min

AU - Ahn, Sang Hoon

AU - Park, Do Joong

AU - Kim, Hyung Ho

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Despite adjuvant chemotherapy, patients with advanced gastric cancer (AGC) often develop recurrence, and the peritoneum is the most common site of recurrence. Therefore, intraperitoneal chemotherapy (IPC) has been proposed as a treatment option. The aim of this study was to select the eligible patients for application of IPC. Methods: A total of 805 patients with AGC who underwent curative D2 gastrectomy between May 2003 and December 2009 were included in this study. Risk factors for peritoneal recurrence were analyzed. Results: Recurrence developed in 245 patients (30.4 %). The first site of recurrence was the peritoneum in 144 patients (58.8 %), and the 5-year peritoneal recurrence-free survival was 79.3 %. Depth of tumor invasion ≥T3, extensive lymph node metastasis (N3), Bormann type 4, infiltrative type (Ming's classification), and venous invasion were independent risk factors for peritoneal recurrence. In subgroup analysis with patients who had received adjuvant chemotherapy (n = 481), depth of tumor invasion ≥T3, Bormann type 4, infiltrative type (Ming's classification), and venous invasion were independent risk factors for peritoneal recurrence. When a peritoneal recurrence risk index was made with each risk factor assigned 1 point (2 points for T4 stage), peritoneal recurrence rates with 0, 1, 2, 3, 4, or 5 points were 0 %, 3.9 %, 13.1 %, 33.3 %, 44.0 %, and 72.0 %, respectively, in those patients. Conclusions: Patients at higher risk for peritoneal recurrence can be identified from the findings of this study. Further prospective studies are required to evaluate the usefulness of IPC for these patients.

AB - Background: Despite adjuvant chemotherapy, patients with advanced gastric cancer (AGC) often develop recurrence, and the peritoneum is the most common site of recurrence. Therefore, intraperitoneal chemotherapy (IPC) has been proposed as a treatment option. The aim of this study was to select the eligible patients for application of IPC. Methods: A total of 805 patients with AGC who underwent curative D2 gastrectomy between May 2003 and December 2009 were included in this study. Risk factors for peritoneal recurrence were analyzed. Results: Recurrence developed in 245 patients (30.4 %). The first site of recurrence was the peritoneum in 144 patients (58.8 %), and the 5-year peritoneal recurrence-free survival was 79.3 %. Depth of tumor invasion ≥T3, extensive lymph node metastasis (N3), Bormann type 4, infiltrative type (Ming's classification), and venous invasion were independent risk factors for peritoneal recurrence. In subgroup analysis with patients who had received adjuvant chemotherapy (n = 481), depth of tumor invasion ≥T3, Bormann type 4, infiltrative type (Ming's classification), and venous invasion were independent risk factors for peritoneal recurrence. When a peritoneal recurrence risk index was made with each risk factor assigned 1 point (2 points for T4 stage), peritoneal recurrence rates with 0, 1, 2, 3, 4, or 5 points were 0 %, 3.9 %, 13.1 %, 33.3 %, 44.0 %, and 72.0 %, respectively, in those patients. Conclusions: Patients at higher risk for peritoneal recurrence can be identified from the findings of this study. Further prospective studies are required to evaluate the usefulness of IPC for these patients.

KW - Advanced gastric cancer

KW - Intraperitoneal chemotherapy

KW - Peritoneal recurrence

UR - http://www.scopus.com/inward/record.url?scp=84903554402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903554402&partnerID=8YFLogxK

U2 - 10.1007/s10120-013-0306-2

DO - 10.1007/s10120-013-0306-2

M3 - Article

C2 - 24101155

AN - SCOPUS:84903554402

VL - 17

SP - 529

EP - 536

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 3

ER -